Conference call to be held Tuesday, August 1, 2023, at 8:30 AM ET
NEW YORK, July 31, 2023 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Tuesday, August 1, 2023, at 8:30 AM ET to discuss results for the second quarter 2023 and provide a business outlook for remainder of the year. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call.
In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call.
TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received U.S. Food and Drug Administration (FDA) approval for BRIUMVI® (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease as well as European Commission (EC) approval for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on Twitter @TGTherapeutics and on LinkedIn.
CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
"Federal Marijuana Reform Is Coming-But FDA-Ready Companies Will Benefit the most" Duane Boise CEO MMJ…
PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / December 17, 2025 / TruMerit, a worldwide leader in…
NORTHAMPTON, MA / ACCESS Newswire / December 17, 2025 / Originally published on Bristol Myers…
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - Restart Life Sciences Corp. (CSE: HEAL)…
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - Restart Life Sciences Corp. (CSE: HEAL)…
12 early-career researchers will receive three years of support to carry out projects at the…